Isochromosome 17q10 associated with basophilia in primary myelofibrosis while with JAK2 inhibitor

Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience

“…During the period of 2011 to 2017, we found 14 patients with i17q (either sole or with complex cytogenetic abnormalities) with a median survival of 10.4 months. Isochromosome 17q is often seen as a secondary evolution during blast crisis phase of CML and other myeloid neoplasms as reported in the literature and heralds an aggressive clinical course [3], [4] Isochromosome 17q is associated with a poor prognosis in patients with myeloid neoplasms. [5], [6] An improved survival trend was noted in our patients who underwent HSCT compared to those patients who were managed by traditional chemotherapy only.…”